Although mTOR inhibitors have shown great potential as antitumor agents, and CCI-779 has been approved by the US Food and Drug Administration (FDA) as a first-line treatment for patients with advanced refractory renal cell carcinoma [43]. Here, MTOR is linked to renal cell carcinoma.